Purpose | Board Meetings Date | Announcement Date |
---|---|---|
Board Meeting | 23 Apr 2025 | 20 Apr 2025 |
Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/04/2025 inter alia to consider and approve To consider and approve the proposal for raising of funds by way of issue of equity shares or any other eligible securities through one or more of the permissible modes including but not limited to qualified institutions placement rights issue preferential issue further public offer etc. Outcome of Board Meeting (As Per Bse Announcement Dated on :23.04.2025) | ||
Board Meeting | 4 Apr 2025 | 1 Apr 2025 |
Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/04/2025 inter alia to consider and approve Intimation of Board meeting for raising funds through issuance of Commercial Papers or through any other mode Issuance of Commercial Papers up to an amount not exceeding Rs. 600 Crores in one or more tranches on private placement basis (As Per Bse Announcement Dated on 04.04.2025) | ||
Board Meeting | 30 Jan 2025 | 3 Jan 2025 |
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31 2024 amongst other routine matters. Outcome of Board Meeting dated 30.01.2025 (As Per Bse Announcement Dated on 30.01.2025) | ||
Board Meeting | 27 Jan 2025 | 22 Jan 2025 |
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 ,inter alia, to consider and approve Raising of Funds through issuance of Commercial Papers (CPs) or through any other mode on private placement basis. Outcome of Board Meeting held on 27.01.2025 (As Per BSE Announcement Dated on 27/01/2025) | ||
Board Meeting | 30 Oct 2024 | 3 Oct 2024 |
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2024 inter alia to consider and approve Intimation for board meeting Unaudited Standalone and Consolidated Financial Results for quarter and half-year ended September 30, 2024 Outcome of Board Meeting dated October 30, 2024 (As Per BSE Announcement dated on 30.10.2024) | ||
Board Meeting | 8 Aug 2024 | 17 Jul 2024 |
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve approval of the un-audited financial results for the quarter ended 30.06.2024. Outcome of the Board Meeting held on 08.08.2024 (As Per BSE Announcement Dated on: 08/08/2024) | ||
Board Meeting | 11 Jun 2024 | 11 Jun 2024 |
Appointment of Interim CFO | ||
Board Meeting | 16 May 2024 | 10 Apr 2024 |
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 ,inter alia, to consider and approve Audited standalone and consolidated results and to consider recommendation of dividend, if any, amongst other routine matters. The Board has approved the appointment of Mr. Atul Dhawan as an Additional Director (Non Executive and Independent) of the Company w.e.f. May 16, 2024. Outcome of Board Meeting held on May 16, 2024 Outcome of Board meeting and Audited Financials Results for the financial year ended 31.03.2024 The Board recommended a final dividend at the rate of 10% i.e. Re. 0.50 per equity share, subject to the shareholders approval. (As Per BSE Announcement dated on 16.05.2024) |
The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.
Here are some of the stocks that may see significant price movement today: LTIMindtree, Dalmia Bharat, Bajaj Housing, etc.
Jobevne is a vascular endothelial growth factor (VEGF) impediment that sticks with VEGF and restrain the interaction with its receptors.
The first approval is for the 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths of Lenalidomide Capsules.
Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.
The drug is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults who have shown resistance or intolerance to prior therapy.
Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza.
As per the company, YESINTEK shall be available in all the same formulations currently provided by Stelara.
Here are some of the stocks that may see significant price movement today: Biocon, NTPC Green Energy, LIC, etc.
Biocon's EBITDA increased by 16% YoY to ₹787 crore, which shows improved operational performance.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.